Scinai Immunotherapeutics Ltd (SCNI) News & EventsSCNIScinai Immunotherapeutics Ltd

Scinai Immunotherapeutics Signs Securities Purchase Agreement, Raises Approximately $4 Million

Scinai Immunotherapeutics announced that it has entered into a securities purchase agreement with an existing life sciences institutional investor for the purchase and sale of 2,458,334 American Depositary Shares, each ADS representing 40,000 ordinary shares, together with Series A-1 warrants to purchase up to 3,687,501 ADSs, at an exercise price of $1.20 per ADS, exercisable immediately with a term of five years, at a combined purchase price of $1.20 per ADS and accompanying warrants. Each pre-funded warrant will have a remaining exercise price of $0.0001 per ADS. In addition, the Company entered into a warrant inducement agreement with the same investor for the immediate cash exercise of warrants issued in April 2026 to purchase an aggregate of 879,194 ADSs at a reduced exercise price of $1.20 per ADS. In consideration for the immediate exercise in full of the Existing Warrants for cash, the investor will receive in a private placement new unregistered Series A-1 warrants to purchase up to 1,318,791 ADSs. The New Warrants will have an exercise price of $1.20 per ADS, will be exercisable immediately, and will expire five years from the date of issuance. The aggregate gross proceeds from the private placement and the warrant inducement transaction are expected to be approximately $4M, before deducting placement agent fees and expenses. These proceeds exclude any future proceeds from the exercise of the newly issued Series A-1 warrants. The closing of the transactions is expected to occur on or about October 15, 2026, subject to satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the transactions.

Scinai Biopharma Signs $5.1M Agreement with U.S. Company

Scinai Immunotherapeutics' wholly owned subsidiary Scinai Biopharma Services has entered into a definitive development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company. The agreement expands a previously disclosed customer engagement and includes approximately $5.1M in committed base service fees. The services are expected to contribute to revenue during 2026 and 2027 as the relevant performance obligations are satisfied, with stability services continuing beyond 2027. Advance and milestone payments for the committed services are expected to support cash flow and working capital during project execution. Potential additional clinical manufacturing has a combined indicative, uncommitted service-fee value of $5.85M, with activities contemplated for late 2027 through the first half of 2028.

Company Not Selling Shares, Stockholders Offering 2.71M ADS

This filing relates to the offer and sale from time to time by the selling stockholders of up to 2.71M American depositary shares, or ADSs. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.